Enhanced surveillance for Salmonella Newport

CMAJ. Canadian Medical Association Journal

Volumn 171, Issue 2, 2004, Pages 127-128

  Weir, Erica ^a   Doré, Kathryn ^b   Currie, Andrea ^c  

^a Frontenac Lennox A   (Canada)

^b Surveillance Section

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIUM CULTURE; CANADA; CLINICAL FEATURE; CORRELATION ANALYSIS; ENTEROBACTERIACEAE; EPIDEMIC; FOOD INDUSTRY; GOVERNMENT; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; PATIENT MONITORING; POPULATION RESEARCH; PREVENTIVE MEDICINE; PUBLIC HEALTH; RISK ASSESSMENT; SALMONELLA; SALMONELLOSIS; SEROTYPING; SHORT SURVEY; AGED; ANIMAL; ANIMAL SALMONELLOSIS; ARTICLE; CATTLE; ISOLATION AND PURIFICATION; METHODOLOGY; NEWBORN; PATHOGENICITY; SALMONELLA ENTERICA;

AGED; ANIMALS; CANADA; CATTLE; DISEASE OUTBREAKS; HUMANS; INFANT, NEWBORN; ONTARIO; POPULATION SURVEILLANCE; PUBLIC HEALTH; SALMONELLA ENTERICA; SALMONELLA INFECTIONS; SALMONELLA INFECTIONS, ANIMAL;

EID: 3442887387     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1041038     Document Type: Short Survey

References (4)

1. Outbreak of multidrug-resistant Salmonella Newport - United States, January-April 2002. MMWR Morb Mortal Wkly Rep 2002;51(25):545-8.
2. Gupta A, Fontana J, Crowe C, Bolstorff B, Stout A, Van Duyne S, et al. Emergence of multidrug-resistant Salmonella enterica serotype Newport infections resistant to expanded-spectnun cephalosporins in the United States. J Infect Dis 2003;188:1707-16.
3. Innes P. Multi-drug resistant Salmonella Newport. Toronto: Ontario Ministry of Agriculture and Food; 2003. Available: www.gov.on.ca /OMAFRA/english/livestock/vet/facts /info_salm.htm (accessed 2004 June 23).
4. Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS). Ottawa: Health Canada; 2002. Available: (English) www.hc-sc .gc.ca/pphb-dgspsp/cipars-picra/index .html (accessed 2004 June 23).